13 Heparin-induced thrombocytopenia: pathophysiology and clinical concerns

MD Andreas Greinacher (Professor)
{"title":"13 Heparin-induced thrombocytopenia: pathophysiology and clinical concerns","authors":"MD Andreas Greinacher (Professor)","doi":"10.1016/S0950-3536(98)80061-9","DOIUrl":null,"url":null,"abstract":"<div><p>Heparin-induced thrombocytopenia (HIT) is a severe immunological adverse effect of heparin treatment. Recently the pathogenesis of HIT has been resolved regarding the mechanisms of platelet activation, the nature of the most important antigens and the involvement of the clotting cascade. HIT seems to be associated with massive generation of thrombin, which contributes to the thromboembolic complications. Based on these findings, treatment of patients with acute HIT should include cessation of all heparins and further treatment with an anticoagulant with antithrombin activity. Currently, the two most important compounds for further anticoagulation of HIT-patients are danaparoid-sodium and recombinant hirudin.</p></div>","PeriodicalId":77029,"journal":{"name":"Bailliere's clinical haematology","volume":"11 2","pages":"Pages 461-474"},"PeriodicalIF":0.0000,"publicationDate":"1998-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0950-3536(98)80061-9","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bailliere's clinical haematology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0950353698800619","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Heparin-induced thrombocytopenia (HIT) is a severe immunological adverse effect of heparin treatment. Recently the pathogenesis of HIT has been resolved regarding the mechanisms of platelet activation, the nature of the most important antigens and the involvement of the clotting cascade. HIT seems to be associated with massive generation of thrombin, which contributes to the thromboembolic complications. Based on these findings, treatment of patients with acute HIT should include cessation of all heparins and further treatment with an anticoagulant with antithrombin activity. Currently, the two most important compounds for further anticoagulation of HIT-patients are danaparoid-sodium and recombinant hirudin.

肝素诱导的血小板减少症:病理生理学和临床关注
肝素诱导的血小板减少症(HIT)是肝素治疗的严重免疫不良反应。近年来,HIT的发病机制已经从血小板活化的机制、最重要抗原的性质和凝血级联反应的参与等方面得到了解决。HIT似乎与凝血酶的大量产生有关,这有助于血栓栓塞并发症。基于这些发现,急性HIT患者的治疗应包括停用所有肝素并进一步使用具有抗凝血酶活性的抗凝血剂。目前,对hit患者进行进一步抗凝治疗的两种最重要的化合物是丹那巴苷钠和重组水蛭素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信